{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T09:16:23Z","timestamp":1780391783734,"version":"3.54.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,7,10]]},"DOI":"10.7759\/cureus.41647","type":"journal-article","created":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T16:17:14Z","timestamp":1689005834000},"source":"Crossref","is-referenced-by-count":1,"title":["Adverse Events of Latent Tuberculosis Treatment With Isoniazid in People Living With HIV: A Case-Control Study in a Resource-Rich Setting"],"prefix":"10.7759","author":[{"given":"Ant\u00f3nio","family":"Carlos Silveira Machado","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Crist\u00f3v\u00e3o","family":"Figueiredo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiago","family":"Teixeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Azevedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joana","family":"Fragoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Nunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Coutinho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu\u00eds","family":"Malheiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1111\/resp.13346","article-title":"Latent tuberculosis infection: Opportunities and challenges","volume":"23","author":"Chee CB","year":"2018","unstructured":"Chee CB, Reves R, Zhang Y, Belknap R. Latent tuberculosis infection: Opportunities and challenges. Respirology. 2018, 23:893-900. 10.1111\/resp.13346","journal-title":"Respirology"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/emi.2016.10","article-title":"Updates on the risk factors for latent tuberculosis reactivation and their managements","volume":"5","author":"Ai JW","year":"2016","unstructured":"Ai JW, Ruan QL, Liu QH, Zhang WH. Updates on the risk factors for latent tuberculosis reactivation and their managements. Emerg Microbes Infect. 2016, 5:e10. 10.1038\/emi.2016.10","journal-title":"Emerg Microbes Infect"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.rr6901a1","article-title":"Guidelines for the treatment of latent tuberculosis infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020","volume":"69","author":"Sterling TR","year":"2020","unstructured":"Sterling TR, Njie G, Zenner D, et al.. Guidelines for the treatment of latent tuberculosis infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020. MMWR Recomm Rep. 2020, 69:1-11. 10.15585\/mmwr.rr6901a1","journal-title":"MMWR Recomm Rep"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.12.0677","article-title":"Isoniazid preventive treatment: Predictors of adverse events and treatment completion","volume":"17","author":"Codecasa LR","year":"2013","unstructured":"Codecasa LR, Murgia N, Ferrarese M, et al.. Isoniazid preventive treatment: Predictors of adverse events and treatment completion. Int J Tuberc Lung Dis. 2013, 17:903-8. 10.5588\/ijtld.12.0677","journal-title":"Int J Tuberc Lung Dis"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s11908-020-00726-x","article-title":"Latent tuberculosis and HIV infection","volume":"22","author":"Bares SH","year":"2020","unstructured":"Bares SH, Swindells S. Latent tuberculosis and HIV infection. Curr Infect Dis Rep. 2020, 22:17. 10.1007\/s11908-020-00726-x","journal-title":"Curr Infect Dis Rep"},{"key":"ref6","article-title":"Manual de Tuberculose e Micobact\u00e9rias n\u00e3o Tuberculosas","author":"Programa Nacional Para a Tuberculose","year":"2020","unstructured":"Programa Nacional Para a Tuberculose. Manual de Tuberculose e Micobact\u00e9rias n\u00e3o Tuberculosas. Dire\u00e7\u00e3o-Geral da Sa\u00fade , Lisboa; 2020."},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.3954","article-title":"Screening for latent tuberculosis infection in adults: updated evidence report and systematic review for the US Preventive Services Task Force","volume":"329","author":"Jonas DE","year":"2023","unstructured":"Jonas DE, Riley SR, Lee LC, et al.. Screening for latent tuberculosis infection in adults: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2023, 329:1495-509. 10.1001\/jama.2023.3954","journal-title":"JAMA"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.7326\/M17-0609","article-title":"Treatment of latent tuberculosis infection: An updated network meta-analysis","volume":"167","author":"Zenner D","year":"2017","unstructured":"Zenner D, Beer N, Harris RJ, Lipman MC, Stagg HR, van der Werf MJ. Treatment of latent tuberculosis infection: An updated network meta-analysis. Ann Intern Med. 2017, 167:248-55. 10.7326\/M17-0609","journal-title":"Ann Intern Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s41999-021-00481-9","article-title":"Adverse drug reactions in older adults: A narrative review of the literature","volume":"12","author":"Zazzara MB","year":"2021","unstructured":"Zazzara MB, Palmer K, Vetrano DL, Carf\u00ec A, Onder G. Adverse drug reactions in older adults: A narrative review of the literature. Eur Geriatr Med. 2021, 12:463-73. 10.1007\/s41999-021-00481-9","journal-title":"Eur Geriatr Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.puhe.2021.08.017","article-title":"Economic relationships and health inequalities: Improving public health recommendations","volume":"199","author":"Sayer A","year":"2021","unstructured":"Sayer A, McCartney G. Economic relationships and health inequalities: Improving public health recommendations. Public Health. 2021, 199:103-6. 10.1016\/j.puhe.2021.08.017","journal-title":"Public Health"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1843.2006.00941.x","article-title":"Antituberculosis drugs and hepatotoxicity","volume":"11","author":"Yew WW","year":"2006","unstructured":"Yew WW, Leung CC. Antituberculosis drugs and hepatotoxicity. Respirology. 2006, 11:699-707. 10.1111\/j.1440-1843.2006.00941.x","journal-title":"Respirology"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2007.05207.x","article-title":"Antituberculosis drug-induced hepatotoxicity: Concise up-to-date review","volume":"23","author":"Tostmann A","year":"2008","unstructured":"Tostmann A, Boeree MJ, Aarnoutse RE, de Lange WC, van der Ven AJ, Dekhuijzen R. Antituberculosis drug-induced hepatotoxicity: Concise up-to-date review. J Gastroenterol Hepatol. 2008, 23:192-202. 10.1111\/j.1440-1746.2007.05207.x","journal-title":"J Gastroenterol Hepatol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200510-1666ST","article-title":"An official ATS statement: Hepatotoxicity of antituberculosis therapy","volume":"174","author":"Saukkonen JJ","year":"2006","unstructured":"Saukkonen JJ, Cohn DL, Jasmer RM, et al.. An official ATS statement: Hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med. 2006, 174:935-52. 10.1164\/rccm.200510-1666ST","journal-title":"Am J Respir Crit Care Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy082","article-title":"Cytokine-mediated systemic adverse drug reactions in a drug-drug interaction study of dolutegravir with once-weekly isoniazid and rifapentine","volume":"67","author":"Brooks KM","year":"2018","unstructured":"Brooks KM, George JM, Pau AK, et al.. Cytokine-mediated systemic adverse drug reactions in a drug-drug interaction study of dolutegravir with once-weekly isoniazid and rifapentine. Clin Infect Dis. 2018, 67:193-201. 10.1093\/cid\/ciy082","journal-title":"Clin Infect Dis"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12885","article-title":"Mechanism of isoniazid-induced hepatotoxicity: Then and now","volume":"81","author":"Metushi I","year":"2016","unstructured":"Metushi I, Uetrecht J, Phillips E. Mechanism of isoniazid-induced hepatotoxicity: Then and now. Br J Clin Pharmacol. 2016, 81:1030-6. 10.1111\/bcp.12885","journal-title":"Br J Clin Pharmacol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1021\/tx500013z","article-title":"Mild isoniazid-induced liver injury in humans is associated with an increase in Th17 cells and T cells producing IL-10","volume":"27","author":"Metushi IG","year":"2014","unstructured":"Metushi IG, Zhu X, Chen X, Gardam MA, Uetrecht J. Mild isoniazid-induced liver injury in humans is associated with an increase in Th17 cells and T cells producing IL-10. Chem Res Toxicol. 2014, 27:683-9. 10.1021\/tx500013z","journal-title":"Chem Res Toxicol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.822576","article-title":"Th17 CD4+ T-cell as a preferential target for HIV reservoirs","volume":"13","author":"Renault C","year":"2022","unstructured":"Renault C, Veyrenche N, Mennechet F, et al.. Th17 CD4+ T-cell as a preferential target for HIV reservoirs. Front Immunol. 2022, 13:822576. 10.3389\/fimmu.2022.822576","journal-title":"Front Immunol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2249.1999.00865.x","article-title":"IL-10 in HIV infection: Increasing serum IL-10 levels with disease progression--down-regulatory effect of potent anti-retroviral therapy","volume":"116","author":"Stylianou E","year":"1999","unstructured":"Stylianou E, Aukrust P, Kvale D, M\u00fcller F, Fr\u00f8land SS. IL-10 in HIV infection: Increasing serum IL-10 levels with disease progression--down-regulatory effect of potent anti-retroviral therapy. Clin Exp Immunol. 1999, 116:115-20. 10.1046\/j.1365-2249.1999.00865.x","journal-title":"Clin Exp Immunol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2014.07.006","article-title":"Targeting Th17 cells in autoimmune diseases","volume":"35","author":"Yang J","year":"2014","unstructured":"Yang J, Sundrud MS, Skepner J, Yamagata T. Targeting Th17 cells in autoimmune diseases. Trends Pharmacol Sci. 2014, 35:493-500. 10.1016\/j.tips.2014.07.006","journal-title":"Trends Pharmacol Sci"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/163686-adverse-events-of-latent-tuberculosis-treatment-with-isoniazid-in-people-living-with-hiv-a-case-control-study-in-a-resource-rich-setting","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:03:48Z","timestamp":1707509028000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/163686-adverse-events-of-latent-tuberculosis-treatment-with-isoniazid-in-people-living-with-hiv-a-case-control-study-in-a-resource-rich-setting"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,10]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.41647","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7,10]]}}}